Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/351396
Type: Artigo
Title: We know how to prescribe natalizumab for multiple sclerosis, but do we know how to withdraw it?
Author: Fragoso, Y.D.a,bEmail Author, Arruda, N.M.c, Arruda, W.O.d, Brooks, J.B.B.a, Correa, E.C.e, Damasceno, A.f, Damasceno, C.A.g, Ferreira, M.L.B.c, Giacomo, M.C.B.h, Gomes, S.i, Gonçalves, M.V.M.j, Grzesiuk, A.K.k, Kaimen-Maciel, D.R.l, Lopes, J.l, Machado, S.C.N.m, Oliveira, C.L.S.a, Stella, C.R.A.V.
Abstract: Natalizumab is a potent immunosuppressive monoclonal antibody used for the treatment of multiple sclerosis (MS). While definite guidelines for the safety of natalizumab prescriptions are available in all countries, there are no specific recommendations on how to withdraw the drug if the need arises. There are reports describing MS complications after natalizumab infusions were stopped. Most neurologists seem to stop natalizumab treatment according to their idea on how to best carry out the withdrawal. The present study shows the very different manners in which expert neurologists from 14 MS units in Brazil stopped natalizumab in their patients. The authors concluded that pharmacovigilance on natalizumab must persist after the drug is withdrawn in order to have enough data for adequate recommendations
Subject: Esclerose múltipla
Country: Reino Unido
Editor: Taylor & Francis
Rights: Fechado
Identifier DOI: 10.1586/14737175.2014.874947
Address: https://www.tandfonline.com/doi/abs/10.1586/14737175.2014.874947
Date Issue: 2014
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
2-s2.0-84893060675.pdf255.14 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.